Assembly Biosciences发布长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究积极中期结果,显示复发性生殖器单纯疱疹的病毒排泄率和经病毒确认的生殖器损伤率均有所降低

美股速递
Dec 09, 2025

Assembly Biosciences发布了有关其长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究的积极中期结果,研究表明,复发性生殖器单纯疱疹患者的病毒排泄率和经病毒确认的生殖器损伤率均有所降低。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10